Core Insights - Milestone Pharmaceuticals announced consistent efficacy and safety findings for etripamil nasal spray in managing paroxysmal supraventricular tachycardia (PSVT) across multiple clinical trials [1][3][7] - The data will be presented at the American Heart Association Scientific Sessions 2025, highlighting the potential for self-administration of etripamil to improve patient management of PSVT [1][3] Study Findings - Etripamil demonstrated a median time to conversion of symptomatic PSVT episodes of 18.5 minutes, with a conversion rate of 59.6% by 30 minutes and 63.2% to 75.1% by 60 minutes post-administration [7] - Safety data indicated a low rate of test-dose failures at 1.4% and predominantly mild, transient adverse events localized to the nasal site [7] Product Information - Etripamil is a novel calcium channel blocker nasal spray designed for self-administration, aiming to provide rapid response therapy for PSVT and atrial fibrillation with rapid ventricular response (AFib-RVR) [6][9] - The New Drug Application (NDA) for etripamil, branded as CARDAMYST, is currently under evaluation by the U.S. FDA, with a target decision date set for December 13, 2025 [5][9] Company Overview - Milestone Pharmaceuticals focuses on developing innovative cardiovascular medicines, with etripamil being its lead investigational product aimed at improving the management of heart conditions like PSVT [1][9]